LONDON and MUNICH and NEW DELHI, Jan. 21, 2025 /PRNewswire/ — Datar Cancer Genetics (DCG) today announced the launch of Target-MRD, an advanced molecular residual disease (MRD) monitoring blood test for solid organ cancers. Target-MRD is a blood test based on tumor-agnostic next-generation sequencing (NGS) and customized, tumor-informed droplet digital PCR (dd-PCR) assay.

Scientists have developed a way of assessing the ability of red blood cells to deliver oxygen by measuring their shape. This test could improve specialist transplant and transfusion practice as well as blood banking. The research is published in eBioMedicine.

RNA in the human genome’s understudied ‘Wild West’ might be key to regulating genetic disorders like epilepsy, autism

Researchers have found that a new class of light-sensitive proteins are capable of turning off brain cells with light

With the new technique, MIT researchers hope to identify mutations that could be targeted with new cancer therapies.

Researchers at Peter Mac have made a key discovery in liver regeneration that may have important implications for liver cancer. Joint research by Associate Professor Andrew Cox and Professor Mark Dawson, published Feb. 15 in Developmental Cell, has identified how the liver is triggered to regrow when damaged.

Researchers at the University of Toronto’s Donnelly Center for Cellular and Biomolecular Research have found nearly one million new exons—stretches of DNA that are expressed in mature RNA—in the human genome.

New technique made human T cells 100 times more potent at killing cancer cells